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Abstract: Brooke-Spiegler syndrome (BSS; OMIM 605041) is an autosomal dominant condition 
characterized by skin appendageal neoplasms including cylindromas, trichoepitheliomas, and/or 
spiradenomas. In 1996, the gene locus for BSS was mapped to 16q12-13, and, in 2000, mutations in the 
cylindromatosis (CYLD) gene were determined to cause BSS, familial cylindromatosis (FC; OMIM 
132700) and multiple familial trichoepithelioma type 1 (MFT1; OMIM 601606). The CYLD gene 
encodes an enzyme with deubiquitinase activity. To date, a total of 95 different diseases-causing 
mutations have been published for the CYLD gene. A summary of mutations identified in Hungarian 
patients and a review of previously published mutations are presented in this update. The majority of 
the sequence changes are frameshift (48%), nonsense (27%), missense (12%) and splice-site (11%) 
mutations; however, two in-frame deletions have also been reported Most mutations are located in 
exons 9-20. Analysis of the identified CYLD gene mutations and the observed BSS, FC and MFT1 clinical 
phenotypes of the patients revealed significant genotype-phenotype correlations. Elucidation of these 
genotype-phenotype correlations is critical for the diagnosis of these rare monogenic skin diseases. In 
addition, characterized correlations may promote the understanding of their mechanisms and may 
hopefully contribute to the development of future therapeutic modalities. 
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SUMMARY 
 
Brooke-Spiegler syndrome (BSS; OMIM 605041) is an autosomal dominant condition 
characterized by skin appendageal neoplasms including cylindromas, trichoepitheliomas, 
and/or spiradenomas. In 1996, the gene locus for BSS was mapped to 16q12-13, and, in 2000, 
mutations in the cylindromatosis (CYLD) gene were determined to cause BSS, familial 
cylindromatosis (FC; OMIM 132700) and multiple familial trichoepithelioma type 1 (MFT1; 
OMIM 601606). The CYLD gene encodes an enzyme with deubiquitinase activity. To date, a 
total of 95 different diseases-causing mutations have been published for the CYLD gene. A 
summary of mutations identified in Hungarian patients and a review of previously published 
mutations are presented in this update. The majority of the sequence changes are frameshift 
(48%), nonsense (27%), missense (12%) and splice-site (11%) mutations; however, two in-
frame deletions have also been reported Most mutations are located in exons 9–20. Analysis 
of the identified CYLD gene mutations and the observed BSS, FC and MFT1 clinical 
phenotypes of the patients revealed significant genotype–phenotype correlations. Elucidation 
of these genotype–phenotype correlations is critical for the diagnosis of these rare monogenic 
skin diseases. In addition, characterized correlations may promote the understanding of their 
mechanisms and may hopefully contribute to the development of future therapeutic 
modalities. 
 
Key words: cylindromatosis gene, Brooke-Spiegler syndrome, familial cylindromatosis, 
familial trichoepitheliomatosis, mutation update 
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BACKGROUND 
 
Brooke-Spiegler syndrome (BSS, OMIM 605041) is a rare monogenic skin disease 
(genodermatosis) characterized by the development of a wide variety of benign skin 
appendageal tumors, such as cylindromas, trichoepitheliomas and/or spiradenomas [Brooke, 
1892; Spiegler, 1899]. The first symptoms of BSS are small skin-colored papules, which 
occur in childhood and adolescence [EVANS, 1954; Sima et al., 2010]. These tumors grow 
slowly in size and continue appear throughout the lifetime of the patient [Blake and Toro, 
2009]. Expression of the papules exhibits wide variation among and within affected families 
[Poblete et al., 2002]. 
Cylindromas are slowly growing benign tumors that are usually located on the scalp and face. 
Typically, they appear as multiple turban-like protrusions on the scalp, which are also referred 
as turban tumors [Uede et al., 2004]. Cylindromas are histologically characterized by dermal 
nodules of epithelial cells: large cells with abundant cytoplasm occur at the center of the 
tumors, where as small basaloid cells occur at the periphery. The cells are lined by membrane-
like basement material and arranged in a ―jigsaw puzzle‖ pattern [Lian and Cockerell, 2005]. 
Cylindromas express hair keratins [Massoumi et al., 2006]. 
Trichoepitheliomas are small benign skin-colored tumors and are typically present at the 
center of the face, mostly around the nose, periorbitally and in the nasolabial folds [Uede et 
al., 2004]. Histologically, trichoepitheliomas are characterized by basaloid cells with 
peripheral palisades that are arranged in nests or cribriform patterns surrounded by dense 
stroma and fibroblasts [Alsaad et al., 2007]. 
Spiradenomas are purple benign nodular tumors, which are usually located on the trunk or 
limbs [Uede et al., 2004]. Histologically, spiradenomas are composed of large tumor nests 
comprising two types of epithelial cells [Obaidat et al., 2007]. Large light-colored cells with 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 4 
abundant cytoplasm at the center of the nests are surrounded by small darker cells at the 
periphery [Obaidat et al., 2007; Michal et al., 1999]. Spiradenomas rarely become malignant 
but can transform into spiradenocarcinomas [Cooper et al., 1985; Engel et al., 1991; Chou et 
al., 2004]. Hybrid tumors can also occur, such as spiradenocylindromas, which exhibit the 
characteristics of both cylindromas and spiradenomas [Kazakov et al., 2005; Kazakov et al., 
2008; Pizinger and Michal, 2000]. 
BSS is transmitted as an autosomal dominant condition affecting males and females equally 
[GUGGENHEIM and Schnyder, 1961]. BSS and its phenotypic variants were independently 
mapped to chromosome 16q12-q13 by several groups [Fenske et al., 2000; Biggs et al., 1995; 
Biggs et al., 1996; Takahashi et al., 2000]. Within the mapped region, the cylindromatosis 
gene (CYLD) was identified as the causative gene responsible for the development of the 
disease [Takahashi et al., 2000; Bignell et al., 2000]. The CYLD gene (GenBank accession 
number NM_015247) spans 56 kb and contains 20 exons, the first 3 of which are untranslated, 
and 19 introns. Of the 17 known splice variants, 13 affect protein coding regions, and the 
remaining produce non-coding transcripts (http://ensemble.org). The tumor suppressing 
CYLD gene encodes an enzyme with deubiquitinase activity. The CYLD enzyme post-
translationally modifies its target proteins by removing Lys63-linked ubiquitin chains 
[Kovalenko et al., 2003]. The protein interacts with several members of the NF-ĸB signaling 
pathway, including the TRAF2, TRAF6, NEMO and BCL3 proteins, acting as a negative 
regulator [Hutti et al., 2009].  
In 2000, the first 21 mutations of the CYLD gene were identified in the affected members of 
21 families with familial cylindromatosis (FC; OMIM 132700), a clinical variant of BSS 
[Bignell et al., 2000]. Since 2000, several reports have described mutations in the CYLD gene 
in different cases from around the world [Blake and Toro, 2009]. In addition to BSS and FC, 
mutations of the CYLD gene have also been reported in patients with multiple familial 
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trichoepithelioma type 1 (MFT1; OMIM 601606) [Hu et al., 2003]. BSS, FC and MFT1 show 
overlapping phenotypic features: some BSS patients develop multiple skin appendage tumors 
including cylindromas, trichoepitheliomas, and spiradenomas, whereas patients with FC 
develop only cylindromas, and patients with MFT1 develop only trichoepitheliomas (Table I) 
[Brooke, 1892] [Spiegler, 1899; Ancell, 1842; Fordyce, 1892; Zhang et al., 2004]. BSS, FC 
and MFT1 were originally described as distinct clinical entities, but due to their overlapping 
clinical symptoms and their manifestation within the same families, they are now considered 
as a clinical variants that represent a phenotypic spectrum of a single entity [Lee et al., 2005; 
Welch et al., 1968; Young et al., 2006; Oranje et al., 2008].  
To date, a total of 95 mutations have been reported for the CYLD gene. Each of the clinical 
variants is associated with approximately one third of the known mutations: BSS (35%), 
MFT1 (36%) and FC (41%). Note that some of the mutations (12%) were detected in two or 
three different clinical variants: the presence of the c.1112C/A p.S371X, c.2272C/T p.R758X 
and c.2806C/T p.R936X nonsense mutations can lead to the development of all three clinical 
variants [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 2011; 
Lv et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011; 
Oiso et al., 2004; Zhang et al., 2006; Kazakov et al., 2009; Kazakov et al., 2011; Nagy et al., 
2013]. Therefore, it has been hypothesized that BSS, FC and MFT1 are not different disease 
entities, but represent a phenotypic spectrum of the same disease. 
 
SUMMARY OF HUNGARIAN BSS PATIENTS 
 
In Hungary, mutation screening for the CYLD gene has been available since 2010. Screening 
has been performed with direct sequencing of all coding regions and flanking introns of the 
CYLD gene. Once a putative causative variant was identified in a patient, the available, 
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clinically symptom-free family members and unrelated, healthy control individuals were also 
investigated. To our knowledge, our workgroup is the only one in Hungary that performs 
genetic screening for BSS, FC and MFT1.  
We have identified two Hungarian pedigrees with BSS. One family (Pedigree I) is located in  
Szeged, Hungary; the other (Pedigree II), located in Hungary close to Szekszárd, has 
Bukovinian (Romania) origin. Two affected individuals in Pedigree I — a father and his 
daughter — exhibit mild symptoms on their scalp, middle face and trunk [Linos et al., 2011]. 
Pedigree II contains 21 affected family members from seven generations, all of whom exhibit 
severe symptoms also located on their scalp, middle face and trunk [Grossmann et al., 2013]. 
Histological investigation of excised tumors confirmed the presence of cylindromas, 
trichoepitheliomas and spiradenomas for the affected members of both pedigrees, establishing 
the diagnosis of BSS for both families. Mutation screening of the CYLD gene identified a 
novel missense mutation (c.2613C>G, p.His871Gln) in Pedigree I and a recurrent nonsense 
mutation (c.2806C>T, p.Arg936X) in Pedigree II [Grossmann et al., 2013; Linos et al., 2011]. 
The results of functional characterization indicated that the newly identified missense 
mutation from Pedigree I leads to increased ubiquitination of NEMO by modifying the 
deubiquitinating activity of the CYLD protein [Linos et al., 2011]. Since nonsense mutation in 
Pedigree II is recurrent, functional analysis was not carried out for this family. However, the 
same mutation was identified in an Anglo-Saxon pedigree with mild BSS symptoms. We 
performed haplotype analysis for these two geographically distant pedigrees and found that 
the mutations resulted from two independent mutational events, suggesting that is the 
mutations represent a mutational hotspot on the CYLD gene [Grossmann et al., 2013]. Our 
results correlate well with the data reported in the literature supporting the assumption that 
this is a mutational hotspot on the gene: the c.2806C>T, p.Arg936X nonsense mutation has 
been described in all three allelic variants in the disease spectrum caused by CYLD mutations 
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and results in different symptom severity as well as the development of different clinical 
variants [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Saggar et al., 2008; 
Kazakov et al., 2009; Nagy et al., 2013].  
 
VARIANTS OF THE CYLD GENE 
 
A PubMed (http://www.ncbi.nlm.nih.gov/pubmed) literature search was performed to identify 
all patients with CYLD mutations. In addition, data from Hungarian BSS pedigrees carrying 
CYLD mutations have also been included for the present publication. To date, a total of 95 
mutations have been published for the CYLD gene, and the individuals carrying these 
mutations present with phenotypic features of BSS, FC and/or MFT1 (Figure 1). Mutations 
are named according to Human Genome Variation Society (HGVS) nomenclature guidelines 
(www.HGVS.org) and numbered with respect to the CYLD gene reference sequence 
(ENSG00000083799 corresponding to the CYLD gene transcript ENST00000311559).  
The majority of the CYLD mutations (98%) were reported in coding regions. Distribution of 
the mutations within exons is unequal: 99% of the mutations are located within exons 9–20 
(Figure 1). The majority of the sequence changes are frameshift (48%), nonsense (27%), 
missense (12%) or splice-site (11%) mutations; however two in-frame deletions have also 
been reported.  
Approximately half of the identified CYLD mutations (48%) are frameshift mutations arising 
from the insertion or deletion of a small number of nucleotides. The majority of these changes 
lead to the formation of premature stop codons causing truncation and, thus, the dysfunction 
of the CYLD protein (Figure 2). Frameshift mutations are also unequally distributed in the 
CYLD gene (Figure 3): one third are located within the region spanning exons 5–11 [Bignell 
et al., 2000; Grossmann et al., 2013; Saggar et al., 2008; Nasti et al., 2009; Ying et al., 2012; 
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 8 
Liang et al., 2008; Zheng et al., 2004], whereas the rest (66%) occur within the region 
spanning exons 12–20 [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Lv et 
al., 2008] [Saggar et al., 2008; Oiso et al., 2004; Reuven et al., 2013; Chen et al., 2011; Salhi 
et al., 2004; Melly et al., 2012; Heinritz et al., 2006]. Exon 17 is a mutational hotspot, 
containing 20% of all identified frameshift mutations [Bignell et al., 2000; Bowen et al., 
2005; Grossmann et al., 2013; Lv et al., 2008; Saggar et al., 2008; Oiso et al., 2004]. Only a 
quarter of the frameshift mutations (27%) are recurrent, i.e., having been reported by at least 
two studies [Sima et al., 2010; Poblete et al., 2002; Bignell et al., 2000; Bowen et al., 2005; 
Grossmann et al., 2013; Saggar et al., 2008; Oiso et al., 2004; Scheinfeld et al., 2003; Hester 
et al., 2013]. In general, different frameshift mutations can lead to the development of the 
different allelic variants and show phenotypic diversity (Figure 4) [Bignell et al., 2000; 
Saggar et al., 2008; Nasti et al., 2009; Ying et al., 2012; Liang et al., 2008; Scheinfeld et al., 
2003; Hester et al., 2013; Scholz et al., 2010]. 
Nonsense mutations causing truncation and, thus, CYLD protein dysfunction are also 
common, accounting for one quarter (27%) of the CYLD mutations identified so far (Figure 
2). The distribution of nonsense mutations is also unequal in the CYLD gene (Figure 3). One 
third of the nonsense mutations occur within the region spanning exons 9–11 [Sima et al., 
2010; Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 2011; Lv 
et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011; 
Kazakov et al., 2009; Almeida et al., 2008], while the majority (72%) are located within the 
region spanning exons 12–20 [Sima et al., 2010; Bignell et al., 2000; Zhang et al., 2004; 
Young et al., 2006; Oranje et al., 2008; Bowen et al., 2005; Grossmann et al., 2013; Oiso et 
al., 2004; Kazakov et al., 2009; Nagy et al., 2013; Nagy et al., 2012; Zheng et al., 2004; Chen 
et al., 2011; Almeida et al., 2008]. This latter region does not seem to contain a further 
mutational hotspot. It is of interest to note that 25% of the identified nonsense mutations 
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 9 
affect glutamine amino acid residues within the CYLD protein, replacing them with stop 
codons [Sima et al., 2010; Bignell et al., 2000; Grossmann et al., 2013; Zheng et al., 2004; 
Chen et al., 2011; Almeida et al., 2008]. Nearly half of the nonsense mutations (40%) are 
recurrent [Sima et al., 2010; Bignell et al., 2000; Oranje et al., 2008; Bowen et al., 2005; 
Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et 
al., 2008; Van den Ouweland et al., 2011; Oiso et al., 2004; Zhang et al., 2006; Kazakov et 
al., 2009; Kazakov et al., 2011; Nagy et al., 2013; Zheng et al., 2004; Chen et al., 2011]. In 
general, nonsense mutations – even the same mutation in different individuals – lead to the 
development of the different clinical variants; thus, nonsense mutations have been associated 
with the highest phenotypic diversity (Figure 4) [Bignell et al., 2000; Bowen et al., 2005; 
Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et 
al., 2008; Van den Ouweland et al., 2011; Oiso et al., 2004; Zhang et al., 2006; Kazakov et 
al., 2009; Kazakov et al., 2011; Nagy et al., 2013]. 
Missense mutations account for 12% of all mutations identified on the CYLD gene (Figure 2). 
The distribution of missense mutations is also unequal on the CYLD gene (Figure 3): all are 
located within the region spanning exons 12–20 [Sima et al., 2010; Hu et al., 2003; 
Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et 
al., 2008; Van den Ouweland et al., 2011; Kazakov et al., 2009; Nagy et al., 2012; Zheng et 
al., 2004; Almeida et al., 2008; Espana et al., 2007; Wang et al., 2010; Zuo et al., 2007]. Only 
a quarter (27%) of these are recurrent mutations [Sima et al., 2010; Hu et al., 2003; 
Grossmann et al., 2013; Saggar et al., 2008; Kazakov et al., 2009]. In general, missense 
mutations of the CYLD gene have been associated with less phenotypic diversity that other 
kinds of mutations: three quarters (73%) have been reported in MFT1 only (Figure 4) [Nagy 
et al., 2012; Zheng et al., 2004; Almeida et al., 2008; Espana et al., 2007; Wang et al., 2010; 
Zuo et al., 2007].  
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Splice-site mutations account for 11% of all mutations (Figure 2). The distribution of the 
splice-site mutations is also unequal (Figure 3): all of them occur within the region spanning 
exons 10–18 [Bignell et al., 2000; Grossmann et al., 2013; Kacerovska et al., 2013; Van den 
Ouweland et al., 2011; Kazakov et al., 2011; Nasti et al., 2009; Ying et al., 2012; Liang et al., 
2008; Huang et al., 2009; Ly et al., 2004]. Less than a quarter (18%) are recurrent [Bignell et 
al., 2000; Grossmann et al., 2013; Van den Ouweland et al., 2011; Kazakov et al., 2011]. In 
general, splice-site mutations can lead to the development of different clinical variants and 
show phenotypic diversity (Figure 4) [Kacerovska et al., 2013; Van den Ouweland et al., 
2011; Nasti et al., 2009; Liang et al., 2008; Huang et al., 2009].  
In addtion, two in-frame deletions have also been reported: these mutations are located within 
exons 19 and 20. Both of them lead to the development of the FC clinical variant [Van den 
Ouweland et al., 2011].  
 
ETHNIC VARIATION  
 
Mutations of the CYLD gene have been reported among patients with Irish, Japanese, Spanish, 
German, Algerian, Turkish, Hungarian, Slovakian, Italian, Scandinavian, Taiwanese, Turkish, 
Canadian and African backgrounds [Bowen et al., 2005; Kacerovska et al., 2013; Saggar et 
al., 2008; Nagy et al., 2013; Nagy et al., 2012; Nasti et al., 2009; Salhi et al., 2004; Huang et 
al., 2009; Amaro et al., 2010]. However, the majority of the published mutations are reported 
for patients from the UK, USA and China [Bignell et al., 2000; Lv et al., 2008; Ying et al., 
2012; Liang et al., 2008; Zheng et al., 2004; Chen et al., 2011; Wang et al., 2010; Zuo et al., 
2007]. Recurrent mutations have been detected in patients living in geographically distant 
regions: the c.1112C/A p.S371X nonsense mutation was identified in Irish, African American, 
Slovakian and Chinese patients [Bowen et al., 2005; Linos et al., 2011; Lv et al., 2008; 
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Kacerovska et al., 2013] and the c.2806C/T p.R936X nonsense mutation was detected in 
Canadian, American, Anglo-Saxon and Hungarian patients [Bignell et al., 2000; Bowen et al., 
2005; Nagy et al., 2013]. The appearance in geographically distant patients might suggest that 
these recurrent mutations are located in mutational hotspots of the CYLD gene [Nagy et al., 
2013]. Haplotype analysis of patients carrying the same recurrent mutation indicated a 
common ancestor for some patients [Bignell et al., 2000] and independent mutational events 
for others [Nagy et al., 2013]. 
A comparison of ethnicity and allelic variation revealed geographical differences. The clinical 
phenotype of MFT1 was observed mostly in individuals from China but also in African, Afro-
American, Taiwanese, Algerian, Turkish, Italian and Spanish patients [Lv et al., 2008; 
Kacerovska et al., 2013; Liang et al., 2008; Zheng et al., 2004; Chen et al., 2011; Wang et al., 
2010; Zuo et al., 2007]. The majority of patients exhibiting the FC clinical variant were from 
the UK and the USA, but some patients were from Italy and Ireland [Bignell et al., 2000; 
Bowen et al., 2005; Nasti et al., 2009]. Like FC, the majority of patients presenting the BSS 
clinical variant were from the UK and the USA; however, patients from Hungary, Slovakia, 
Italy, Scandinavia, Spain and Canada have also been reported [Bignell et al., 2000; Bowen et 
al., 2005; Kacerovska et al., 2013; Nagy et al., 2013; Nagy et al., 2012; Nasti et al., 2009].  
 
BIOLOGICAL RELEVANCE 
 
The protein encoded by the CYLD gene (GenBank NP_056062), consisting of 956 amino 
acids with a molecular weight of approximately 120 kD, exhibits deubiquitinase activity. The 
CYLD protein plays a role in the posttranslational modification of several proteins by 
removing lysine 63-linked ubiquitin chains. Lysine 63-linked polyubiquitination affects the 
interactions among proteins by creating specific recognition sites for other proteins. However, 
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the CYLD protein, which primarily deubiquitinates lysine 63-linked chains, can also process 
lysine 48-linked chains as well [Reiley et al., 2006; Komander et al., 2008]. The known 
interaction partners of the CYLD protein include TNF-receptor-associated factor proteins 
(TRAF2, TRAF6 and TRAF7) and the NEMO protein, a negative regulator of the NF-kB 
signaling pathway [Haglund and Dikic, 2005]. CYLD is involved in the regulation of several 
biological processes, such as cell proliferation and inflammation [Gao et al., 2008]. 
The N-terminal of the CYLD protein can be divided into two regions based on the occurrence 
of the mutations: no mutations have been detected in the region encoded by exons 4 and 5, 
whereas the region encoded by exons 5–11 contains approximately one fifth (18%) of the 
mutations identified to date. The N-terminal of the CYLD protein contains three cytoskeleton-
associated glycine rich domains (CAP-GLY), at which the CYLD protein connects to 
microtubules [Gao et al., 2008]. The N-terminal of the CYLD protein is highly conserved 
through evolution (Figure 5). Mostly frameshift and nonsense mutations occur in this region, 
as well as the two known splice-site mutations [Sima et al., 2010; Bignell et al., 2000; Bowen 
et al., 2005; Grossmann et al., 2013; Kacerovska et al., 2013; Saggar et al., 2008; Kazakov et 
al., 2009] [Nasti et al., 2009; Liang et al., 2008; Zheng et al., 2004; Almeida et al., 2008; Ly et 
al., 2004]. Most frameshift mutations occur in the first (amino acids 127 to 203) and the third 
(amino acids 472 to 540) CAP-GLY domains, whereas most of the nonsense and splice-site 
mutations occur in the region of the third CAP-GLY domain (Figure 3). Frameshift and 
nonsense mutations occurring in this region have been identified for all clinical variants [Sima 
et al., 2010; Bignell et al., 2000; Bowen et al., 2005; Kacerovska et al., 2013; Saggar et al., 
2008; Nasti et al., 2009; Liang et al., 2008; Zheng et al., 2004; Almeida et al., 2008]. The 
splice-site mutations of this region resulted in the development of the BSS or MFT1 clinical 
variants [Grossmann et al., 2013; Kazakov et al., 2009; Ly et al., 2004]. Missense mutation 
has not been detected at the N-terminal of the CYLD protein.  
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The CYLD gene has changed relatively little through evolution: the similarity between the 
human and mouse genes is 94%, and the homology is especially high at the 3' end of the gene 
(Figure 5). This region of the CYLD protein, encoded by exons 12–20, contains the ubiquitin-
specific protease domain that is responsible for the deubiquitinase activity of the protein. This 
region contains the majority (82%) of identified CYLD mutations, including frameshift (72%), 
nonsense (72%) and splice-site (81%) mutations as well as all known missense mutations 
(Figure 3). Mutations of this region are associated with high phenotypic diversity and can lead 
to the development of any of the three clinical variants of the CYLD mutation-caused 
spectrum. Functional studies of the identified mutations suggest that mutations of this region 
may decrease the deubiquitinase activity of the CYLD protein [Nagy et al., 2012].  
 
CLINICAL AND DIAGNOSTIC RELEVANCE 
 
With respect to the clinical symptoms, FC and MFT1 represent the two extremes of the 
CYLD mutation-caused spectrum, where as BSS falls between these two (Table I). All three 
clinical variants exhibit variable expression among and within affected families; however, the 
most extreme differences in the manifested phenotypes have been reported for BSS [Bowen et 
al., 2005; Zhang et al., 2006; Nagy et al., 2013]. The penetrance is high for all three clinical 
variants and increases with age.  
The majority (82%) of CYLD mutations are located between exons 12 and 20, especially in 
and around exons 16 and 17 (16%) (Figure 1). This finding has a significant diagnostic 
relevance, as mutation screening of affected individuals should start by examining this region. 
If no mutation is identified in the coding regions and the flanking introns of exons 12–20, the 
screening can be expanded to exons 5–11.  
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We suggest using direct sequencing for the screening method, as the mutation detection rate is 
high, estimated at 84% [Saggar et al., 2008]. With the identification of the causative mutation, 
prenatal as well as preimplantation genetic diagnosis can be offered to affected families, 
which, as symptoms of all clinical variants can be very stigmatizing, can have a meaningful 
impact on family planning [Nagy et al., 2013].  
Causative therapy is not currently available for BSS patients. However, recent investigation 
demonstrated that tumors with somatic CYLD mutation have impaired tropomyosin kinase 
(TRK) signaling. Treatment with small TRK inhibitor molecule, lestaurtinib, can reduce 
colony formation and proliferation of CYLD mutant tumor cells [Rajan et al., 2011]. These 
data may have huge clinical significance, since lestaurtinib treatment might be a novel 
therapeutic modality for patients suffering from symptoms caused by germline CYLD 
mutations.  
 
GENOTYPE-PHENOTYPE CORRELATIONS  
 
Genotype–phenotype correlations are difficult to establish, as all types of known CYLD 
mutation – frameshift, nonsense, missense and splice-site – lead to the development of each 
clinical variant of the CYLD mutation-caused spectrum. 
For example, frameshift mutations of the CYLD gene have been identified for all clinical 
variants of the CYLD mutation-caused spectrum. Interestingly, most frameshift mutations 
occur in the region of exon 17 [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 
2013; Lv et al., 2008; Saggar et al., 2008; Oiso et al., 2004]. 
In general, nonsense mutations of the CYLD gene exhibit the largest phenotypic diversity. 
Some nonsense mutations (i.e., c.1112C/A p.S371X, c.2272C/T p.R758X and c.2806C/T 
p.R936X) have been detected in patients diagnosed with FC, BSS or MFT1 [Bignell et al., 
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2000; Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; 
Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011; Oiso et al., 2004; 
Zhang et al., 2006; Kazakov et al., 2009; Kazakov et al., 2011; Nagy et al., 2013]. 
Presumably, this is due to the fact that nonsense mutations are the most recurrent (40%) type 
of CYLD mutation [Sima et al., 2010; Bignell et al., 2000; Oranje et al., 2008; Bowen et al., 
2005; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; 
Saggar et al., 2008; Van den Ouweland et al., 2011; Oiso et al., 2004; Zhang et al., 2006; 
Kazakov et al., 2009; Kazakov et al., 2011; Nagy et al., 2013; Zheng et al., 2004; Chen et al., 
2011]. As many recurrent nonsense mutations are due to de novo events, their frequency and 
location indicates mutational hotspots on the CYLD gene [Bignell et al., 2000; Nagy et al., 
2013]. Patients carrying the same nonsense mutation from different mutational events often 
exhibit extreme differences in their clinical manifestations [Nagy et al., 2013]. These 
differences might be the consequences of yet unknown genetic factors that modify the 
development of the phenotype. Nonsense mutations are also responsible for the most variable 
expression within families [Bowen et al., 2005; Zhang et al., 2006; Nagy et al., 2013]. These 
differences might be explained by environmental and/or lifestyle factors. Further studies are 
needed to elucidate putative genetic, environmental or lifestyle factors that are responsible for 
the observed great variation in phenotype.  
Missense mutations of the CYLD gene are more frequently associated only with MFT1 (73%) 
than the other types of mutations [Sima et al., 2010; Hu et al., 2003; Grossmann et al., 2013; 
Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den 
Ouweland et al., 2011; Kazakov et al., 2009; Nagy et al., 2012; Zheng et al., 2004; Almeida et 
al., 2008; Espana et al., 2007; Wang et al., 2010; Zuo et al., 2007]. Missense mutations also 
lead to the development of milder phenotype [Nagy et al., 2012]. This observation might be 
explained by the fact that missense mutations are distributed differently than the other types 
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of mutations: they are located only between exons 12–20 and not at all in the 5' end. In 
general, missense mutations are associated with low phenotypic diversity, as the majority of 
missense mutations result in the MFT1 phenotype [Nagy et al., 2012; Zheng et al., 2004; 
Almeida et al., 2008; Espana et al., 2007; Wang et al., 2010; Zuo et al., 2007]. Moreover, only 
12% of missense mutations are recurrent [Sima et al., 2010; Hu et al., 2003; Grossmann et al., 
2013; Saggar et al., 2008; Kazakov et al., 2009].  
Splice-site mutations of the CYLD gene can lead to the development of any clinical variant of 
the CYLD mutation-caused spectrum, but little is known about their phenotypic significance 
[Kacerovska et al., 2013; Van den Ouweland et al., 2011; Nasti et al., 2009; Liang et al., 
2008; Huang et al., 2009]. 
 
FUTURE PROSPECTS 
 
The comparison of CYLD gene mutations and the observed clinical variation of the patients 
have already revealed significant genotype–phenotype correlations: nonsense mutations are 
associated with the highest phenotypic diversity and recurrence rate, while missense 
mutations are associated with mild symptoms and are strongly associated with the MFT1 
phenotype. Future efforts might provide insight into the clinical significance of frameshift and 
splice-site mutations and further elucidate the mechanism of the different phenotypic variants 
of the CYLD mutation-caused spectrum. We believe that careful investigation of genotype–
phenotype correlations are necessary to promote better understanding of the BSS, FC and 
MFT1 clinical variants and provide insight into the underlying molecular mechanisms. 
Genetic screening and the identification of disease-causing mutations have already had a 
significant impact on prenatal and preimplantation genetic diagnosis for family planning. 
Future genetic studies could also provide a solid basis for the development of novel causative 
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therapies that will be more specific and effective than the symptomatic treatments currently 
available for patients with FC, BSS and MFT1. Recent investigation identified lestaurtinib, a 
small TRK-inhibitor molecule, which might be a promising novel therapeutic modality for 
patients suffering from symptoms caused by germline CYLD mutations. 
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FIGURE LEGENDS 
 
Figure 1. CYLD gene mutations identified to date. 
Figure 2. Frequency of mutation types reported for patients harboring germline CYLD 
mutations.  
Figure 3. Distribution of mutations in the CYLD protein.  
Figure 4. Mutation types and phenotypic diversity.  
Figure 5. Conservation of CYLD protein sequences throughout evolution. Asterisks indicate 
amino acids that are identical for all analyzed species. 
 
Table 1. Allelic variants of the CYLD mutation-caused spectrum. 
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Familial 
cylindromatosis (FC) 
Brooke-Spiegler 
syndrome (BSS) 
Multiple familial 
trichoepithelioma               
type 1 (MFT1)  
OMIM ID 132700 605041 601606 
Clinical 
symptoms  
Predominantly 
cylindromas  
Cylindromas, 
trichoepitheliomas, 
spiradenomas  
Predominantly 
trichoepitheliomas 
CYLD 
mutations  
Any type of mutation Any type of mutation 
Any type of mutation, 
mostly missense 
Table 1
